Business
Biomarker platform COVID-19 update
Biomarker platform COVID-19 update.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n RNS Number : 4030L\n Oxford BioDynamics PLC\n 30 April 2020\n \n \n \n \n 30 April 2020\n \n \n \n \n \n \n \n \n Oxford BioDynamics Plc\n \n \n (\n \"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \n \n \n \n \n Oxford BioDynamics biomarker platform is selected to help identify COVID-19 patients at risk of severe disease and profile patients who will benefit from therapeutic treatment \n \n \n \n \n \n · \n \n Oxford BioDynamics' EpiSwitch\n \n \n \n ä\n \n \n \n technology has been chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the GETAFIX clinical study\n \n \n \n · \n \n Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland are leading the effort to identify patients at risk of severe immune complications and those patients who can benefit from treatment with the anti-viral favipiravir\n \n \n \n · \n \n The EpiSwitch\n \n \n \n ä\n \n \n \n platform has already delivered prognostic and predictive biomarker developments and validations in collaboration with University of Glasgow Professors Iain McInnes and Carl Goodyear, as well as with EMD Serono, Pfizer, Genentech, Roche, Mayo Clinic and Massachusetts General Hospital\n \n \n \n \n \n \n Oxford BioDynamics Plc (AIM:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, using its liquid biopsy platform EpiSwitch\n \n ä\n \n , is pleased to announce its participation in the Chief Scientist Office of Scotland funded biomarker study \"Viral and Immunological Correlates of Clinical Severity and Response to Anti-Viral Therapy for COVID-19\", with respect to the GETAFIX clinical study \"Glasgow Early Treatment Arm Favipiravir (GETAFIX): A randomised controlled study of favipiravir as an early treatment arm of ASTERIX in COVID-19 hospitalised patients\". This study will inform both about COVID-19 disease severity and response to the anti-viral therapy, which is a selective inhibitor of viral RNA-dependent RNA polymerase. \n \n \n \n \n \n These studies are part of nine crucial COVID-19 research projects at the University of Glasgow resulting from a rapid response call aimed at increasing the understanding of the coronavirus...